ClinicalTrials.Veeva

Menu

DISE-HNS Effect Study

A

Antwerp University Hospital (UZA)

Status

Enrolling

Conditions

Obstructive Sleep Apnea

Treatments

Diagnostic Test: Polysomnography
Procedure: Drug-induced sleep endoscopy (DISE)
Device: Hypoglossal nerve stimulation implant

Study type

Interventional

Funder types

Other

Identifiers

NCT06372847
Project ID 6214

Details and patient eligibility

About

The purpose of this study is to assess the site, pattern and degree of upper airway collapse before and during hypoglossal nerve stimulation (HNS) treatment using clinical standard drug-induced sleep endoscopy (DISE) and using a novel, non-invasive method predicting site of collapse from raw polysomnography (PSG) data.

Furthermore, outcomes will be compared between responders and non-responders.

Full description

Patients who will receive hypoglossal nerve stimulation therapy will be recruited at the pre-operative consultation at the department of ENT. As part of the standard procedure, all patients who are eligible for HNS have already undergone DISE.

To be included in the study, the patient should have undergone or is scheduled to undergo a baseline PSG within two years of HNS implantation.

All patients will undergo HNS-implantation and receive HNS-therapy as part of the standard pathway.

One year after HNS-therapy, patients will undergo another PSG as part of routine practice in these patients. An additional DISE will be performed to assess the effect of HNS on the site, pattern and degree of upper airway collapse.

Enrollment

58 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 18 years or older.
  • Eligible for HNS-therapy:
  • AHI between 15 and 65 events/hour
  • BMI under 32 kg/m2
  • Absence of complete concentric collapse of palate (CCC) on DISE
  • Intolerance or failure of continuous positive airway pressure (CPAP)-treatment
  • Intolerance or failure of mandibular advancement device (MAD)-treatment
  • Combination of central and mixed apneas less than 25% of total apneas on recent PSG (not older than two years)
  • Scheduled for HNS-implantation at the Antwerp University Hospital
  • Capable of giving informed consent
  • Baseline polysomnography planned or performed in the last 2 years at the Antwerp University Hospital

Exclusion criteria

  • Patients will not receive HNS-therapy at the Antwerp University Hospital
  • Known medical history of intellectual disability, memory disorders or current psychiatric disorders (psychotic illness, major depression, or acute anxiety attacks as mentioned by the patient).

Trial design

Primary purpose

Basic Science

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

58 participants in 1 patient group

Receiving hypoglossal nerve stimulation (HNS)
Other group
Description:
All included patients will be part of this arm. Patients who are eligible for HNS-therapy for obstructive sleep apnea (OSA) will be invited to participate in the study. Data from the baseline PSG and baseline DISE as part of the standard pathway for HNS-eligibility will be accessed and collected. All patients will undergo HNS-implantation and receive HNS-therapy as part of the standard pathway. After one year of treatment, information from the one-year follow-up PSG as part of the standard pathway will be collected. Furthermore, patients will undergo an additional one-year follow-up DISE.
Treatment:
Device: Hypoglossal nerve stimulation implant
Procedure: Drug-induced sleep endoscopy (DISE)
Diagnostic Test: Polysomnography

Trial documents
2

Trial contacts and locations

1

Loading...

Central trial contact

Eldar Tukanov, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems